EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?

Beata Zaborska, Małgorzata Sikora-Frąc, Krzysztof Smarż iD, Ewa Pilichowska-Paszkiet, Andrzej Budaj, Dariusz Sitkiewicz, Grażyna Sygitowicz iD

International Journal of Molecular Sciences · 23.08.2023 · 24 (17) · 13111

DOI: 10.3390/ijms241713111 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 23.08.2023. Verfasst von Beata Zaborska und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, 04-073 Warsaw, Poland. Hauptthemen laut MEDLINE: Galectin 3, Heart Failure. Die Arbeit wurde bisher 103-mal zitiert (Crossref) und nennt 160 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre of Postgraduate Medical Education, Warsaw, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) is a clinical syndrome with high morbidity and mortality, and its prevalence is rapidly increasing. Galectin-3 (Gal-3) is an important factor in the pathophysiology of HF, mainly due to its role in cardiac fibrosis, inflammation, and ventricular remodeling. Fibrosis is a hallmark of cardiac remodeling, HF, and atrial fibrillation development. This review aims to explore the involvement of Gal-3 in HF and its role in the pathogenesis and clinical diagnostic and prognostic significance. We report data on Gal-3 structure and molecular mechanisms of biological function crucial for HF development. Over the last decade, numerous studies have shown an association between echocardiographic and CMR biomarkers in HF and Gal-3 serum concentration. We discuss facts and concerns about Gal-3’s utility in acute and chronic HF with preserved and reduced ejection fraction for diagnosis, prognosis, and risk stratification. Finally, we present attempts to use Gal-3 as a therapeutic target in HF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Galectin 3Heart FailureHumansAtrial FibrillationHeartPrognosis

Stichwörter der Autor:innen

atrial fibrillationfibrosisgalectin-3heart failure

Substanzen

Galectin 3

Autor:innen und Institutionen

  • Department of Cardiology, Centre of Postgraduate Medical Education, Grochowski Hospital, 04-073 Warsaw, Poland.
  • Department of Laboratory Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.

ORCID-Profile: Krzysztof Smarż, Grażyna Sygitowicz

Förderung

  • Centre of Postgraduate Medical Education, Warsaw, Poland

Zitieren

APA

Zaborska, B., Sikora-Frąc, M., Smarż, K., Pilichowska-Paszkiet, E., Budaj, A., Sitkiewicz, D., & Sygitowicz, G. (2023). The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?. International Journal of Molecular Sciences, 24(17), 13111. https://doi.org/10.3390/ijms241713111

Vancouver

Zaborska B, Sikora-Frąc M, Smarż K, Pilichowska-Paszkiet E, Budaj A, Sitkiewicz D, et al. The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?. International Journal of Molecular Sciences. 2023;24(17):13111. doi:10.3390/ijms241713111

BibTeX
@article{Zaborska2023,
  author = {Zaborska, Beata and Sikora-Frąc, Małgorzata and Smarż, Krzysztof and Pilichowska-Paszkiet, Ewa and Budaj, Andrzej and Sitkiewicz, Dariusz and Sygitowicz, Grażyna},
  title = {The Role of Galectin-3 in Heart Failure—The Diagnostic, Prognostic and Therapeutic Potential—Where Do We Stand?},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {17},
  pages = {13111},
  doi = {10.3390/ijms241713111}
}
Kostenlos starten →